SynthesisAmerican journal of obstetrics and gynecology2022
Does vaginal progesterone prevent recurrent preterm birth in women with a singleton gestation and a history of spontaneous preterm birth? Evidence from a systematic review and meta-analysis.
Synthesis in American journal of obstetrics and gynecology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 59 citations in OpenAlex.
- Nestorone, a potent progestin, exhibits anti-inflammatory activity and prevents preterm birth in murine models of premature labor.American journal of obstetrics and gynecology · 2026Article
- Risk factors for spontaneous preterm birth are mediated through changes in cervical length.Communications medicine · 2025Article
- The Lioness™ device: a prospective non-randomized safety and feasibility study of a novel device for preterm birth delay and prevention.BMC pregnancy and childbirth · 2025Article
- Serum metabolites as diagnostic biomarkers for preterm labor: a metabolomics-based study.BMC pregnancy and childbirth · 2025Article
- Article
- Immune changes in pregnancy: associations with pre-existing conditions and obstetrical complications at the 20th gestational week-a prospective cohort study.BMC medicine · 2024Article
- Prediction model for spontaneous preterm birth less than 32 weeks of gestation in low-risk women with mid-trimester short cervical length: a retrospective cohort study.BMC pregnancy and childbirth · 2024Observational
- The Effect of Maternal Parity on Preterm Birth Risk in Women with Short Mid-Trimester Cervical Length: A Retrospective Cohort Study.Journal of clinical medicine · 2024Article
- Progesterone therapy for prevention of recurrent spontaneous preterm birth in a minority patient population: a retrospective study.BMC pregnancy and childbirth · 2024Article
- Predictive values of cervix length measurement based on transvaginal ultrasonography.Technology and health care : official journal of the European Society for Engineering and Medicine · 2024Article
- The end is where we start from: withdrawal of 17-alpha hydroxyprogesterone caproate to prevent recurrent preterm birth.American journal of obstetrics and gynecology · 2024Article
- Assessment of current biomarkers and interventions to identify and treat women at risk of preterm birth.Frontiers in medicine · 2024Review
- Effects of vaginal progesterone and placebo on preterm birth and antenatal outcomes in women with singleton pregnancies and short cervix on ultrasound: a meta-analysis.Frontiers in medicine · 2024Review
- Construction and validation of a novel nomogram for predicting spontaneous preterm birth in patients with gestational diabetes mellitus.American journal of translational research · 2024Article
- Progesterone, cerclage, pessary, or acetylsalicylic acid for prevention of preterm birth in singleton and multifetal pregnancies - A systematic review and meta-analyses.Frontiers in medicine · 2023Review
- Vaginal progesterone does not prevent recurrent preterm birth in women with a singleton gestation, a history of spontaneous preterm birth, and a midtrimester cervical length >25 mm.American journal of obstetrics and gynecology · 2022Article
- Progesterone: The Key Factor of the Beginning of Life.International journal of molecular sciences · 2022Review
- Association of Vaginal Progesterone Treatment With Prevention of Recurrent Preterm Birth.JAMA network open · 2022Observational
- Use of an Arabin pessary to prevent preterm birth in pregnancy complicated by a short cervix after cervical conization for cervical adenocarcinoma with residual disease: A case report and literature review.Case reports in women's health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo assess the efficacy and safety of vaginal progesterone to prevent recurrent preterm birth and adverse perinatal outcomes in singleton gestations with a history of spontaneous preterm birth. DATA SOURCES: MEDLINE, Embase, LILACS, and CINAHL (from their inception to February 28, 2022), Cochrane databases, Google Scholar, bibliographies, and conference proceedings. STUDY ELIGIBILITY CRITERIA: Randomized controlled trials that compared vaginal progesterone to placebo or no treatment in asymptomatic women with a singleton gestation and a history of spontaneous preterm birth.
methodsThe primary outcomes were preterm birth <37 and <34 weeks of gestation. The secondary outcomes included adverse maternal and perinatal outcomes. Pooled relative risks with 95% confidence intervals were calculated. We assessed the risk of bias in the included studies, heterogeneity (I
resultsTen studies (2958 women) met the inclusion criteria: 7 with a sample size <150 (small studies) and 3 with a sample size >600 (large studies). Among the 7 small studies, 4 were at high risk of bias, 2 were at some concerns of bias, and only 1 was at low risk of bias. All the large studies were at low risk of bias. Vaginal progesterone significantly decreased the risk of preterm birth <37 weeks (relative risk, 0.64; 95% confidence interval, 0.50-0.81; I
conclusionThere is no convincing evidence supporting the use of vaginal progesterone to prevent recurrent preterm birth or to improve perinatal outcomes in singleton gestations with a history of spontaneous preterm birth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.